TheraRadar

Pharma Intelligence, Simplified

Landscape → CNS

Bipolar Disorder

130 clinical trials

43 active
/
130 total (since 2015)
7
Phase 1 Active
16 total
14
Phase 2 Active
49 total
16
Phase 3 Active
40 total
9
Phase 4 Active
35 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Intra-Cellular Therapies, Inc. 4 4 0
Bristol-Myers Squibb 3 0 0
Xenon Pharmaceuticals Inc. 2 0 0
BioXcel Therapeutics Inc 1 2 0
Neurocrine Biosciences 1 1 0
Eli Lilly 1 0 0
Autobahn Therapeutics, Inc. 1 0 0
Alto Neuroscience 1 0 0
NeuroRx, Inc. 0 3 0
NCT06951711 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Bristol-Myers Squibb n=274
NCT06929273 RECRUITING
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bristol-Myers Squibb n=450
NCT07140913 RECRUITING
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Bristol-Myers Squibb n=424
NCT07263022 NOT YET RECRUITING
Cognitive Strategies in Early Psychosis 2
University of Minnesota n=24
NCT07217860 ENROLLING BY INVITATION
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
Xenon Pharmaceuticals Inc. n=400
NCT07172516 RECRUITING
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Xenon Pharmaceuticals Inc. n=400
NCT05603104 RECRUITING
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Dr. Inge Winter n=1,254
NCT05973786 RECRUITING
The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Dr. Inge Winter n=418
NCT06529029 RECRUITING
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Michigan State University n=30
NCT06372964 RECRUITING
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Intra-Cellular Therapies, Inc. n=384
NCT06229210 RECRUITING
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc. n=500
NCT06462612 RECRUITING
Study of Lumateperone in the Treatment of Patients With Bipolar Mania
Intra-Cellular Therapies, Inc. n=350
NCT06462586 RECRUITING
Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
Intra-Cellular Therapies, Inc. n=350
NCT06986460 NOT YET RECRUITING
Low Frequency Right Dorsolateral Pre Frontal Cortical Repetitive TMS for Bipolar Depression
Tyler Kaster n=80
NCT05867849 RECRUITING
Cannabidiol for Bipolar Depression (CBD-BD)
University of British Columbia n=360
NCT04569448 RECRUITING
Brexpiprazole Treatment for Bipolar I Depression
Douglas Mental Health University Institute n=58
NCT06419582 COMPLETED
BHV-7000 Acute Treatment of Bipolar Mania
Biohaven Therapeutics Ltd. n=274
NCT02600494 COMPLETED
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
Intra-Cellular Therapies, Inc. n=554
NCT04285515 COMPLETED
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
Intra-Cellular Therapies, Inc. n=488
NCT02731612 COMPLETED
Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients
Lakshmi N Yatham n=100
NCT04939649 COMPLETED
Ketamine As an Adjunctive Therapy for Major Depression (2)
University of Dublin, Trinity College n=63
NCT02362412 COMPLETED
Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
Astellas Pharma Inc n=22
NCT02918370 COMPLETED
Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
University of Texas Southwestern Medical Center n=75
NCT03395392 COMPLETED
NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
NeuroRx, Inc. n=74
NCT01928446 TERMINATED
Lithium for Suicidal Behavior in Mood Disorders
VA Office of Research and Development n=519
NCT04276883 COMPLETED
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
BioXcel Therapeutics Inc n=380
NCT03674671 SUSPENDED
Ketamine Versus Electroconvulsive Therapy in Depression
University of Ottawa n=240
NCT02600507 COMPLETED
Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression
Intra-Cellular Therapies, Inc. n=529
NCT02800161 COMPLETED
Trehalose as add-on Therapy in Bipolar Depression
Consorcio Centro de Investigación Biomédica en Red (CIBER) n=60
NCT03402152 COMPLETED
NRX101 Glx Biomarker Validation Study
NeuroRx, Inc. n=8
NCT03249376 COMPLETED
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
Intra-Cellular Therapies, Inc. n=381
NCT02726659 TERMINATED
Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's n=1
NCT03310593 TERMINATED
Cannabidiol as an Adjunctive Treatment for Bipolar Depression
Hospital de Clinicas de Porto Alegre n=36
NCT03768726 TERMINATED
Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=23
NCT02519543 COMPLETED
Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder
Cynthia Calkin n=50
NCT02703363 COMPLETED
Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression
Pakistan Institute of Living and Learning n=265
NCT02670538 COMPLETED
Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder
Forest Laboratories n=493
NCT02670551 COMPLETED
Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression
Forest Laboratories n=488
NCT02308956 COMPLETED
Task Sharing for the Care of Severe Mental Disorders in a Low-income Country
University of Cape Town n=324
NCT02423824 COMPLETED
Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists
University Health Network, Toronto n=21

Data: ClinicalTrials.gov